Anti-cancer effect of Mesenchymal Stem

Despite the fact that MSCs are clearly associated to tumor development, the absence of methods for precisely identifying the various MSC populations and the paradoxical association between MSC and tumor has hampered the development of MSC-based oncological therapies. In this study, we try to investigate the effects of human umbilical cord derived (UC-MSCs) and their secretome, alone or compared to 5-FU, on the proliferation of CRC cell lines, their migration ability, and their expression of tumor markers. Chemotherapy combinations including 5-fluorouracil (5-FU) have been the gold standard in the treatment of CRC, but their use is hindered by the development of side effects or chemo-resistance by patients. On the other hand, umbilical cord-derived mesenchymal stem cells (UC-MSCs), bone marrow derived mesenchymal stem cells (BM-MSCs) and adipose tissue derived mesenchymal stem cells (AT-MSCs) and their immunomodulatory cytokines and chemokines, known as the MSC secretome, are showing favorable effects on immune and inflammatory diseases in clinical trials. Due to their tropism to inflammatory signals, mesenchymal stem cells have been used for cell therapy or as a vehicle to deliver therapeutics to tumors. Measurements of colorectal cancer tumor marker proteins were computed by ELISA. Proliferative, apoptosis and anti-inflammatory effects of the MSCs were measured by Flow cytometry (FCM). MMPs expression was measured by RT-PCR.